Abstract | BACKGROUND: METHODS: RESULTS: Thirty-four patients (81%) achieved an objective clinical remission; 3 patients (7%) achieved a clinical complete remission, 31 (74%) a partial remission. Six patients (14%) achieved pathologic complete remission. Sixteen patients were treated with paclitaxel, 7 of them (44%) were able to undergo mastectomy. Median time to progression ( TTP) was 22 months. Median overall survival (OS) was 46 months. Concordance between clinical and pathologic response was documented in only 8 patients (24%). No differences in TTP and OS compared with a historical group of 178 IBC patients treated with anthracycline-based regimens. CONCLUSIONS:
Paclitaxel improves tumor resectability in anthracycline-refractory IBC. The impact of paclitaxel on the prognosis of IBC needs to be better evaluated in future trials using more dose-intensive schedules of administration. New imaging modalities may contribute to improve assessment of response to IC.
|
Authors | M Cristofanilli, A U Buzdar, N Sneige, T Smith, B Wasaff, N Ibrahim, D Booser, E Rivera, J L Murray, V Valero, N Ueno, E S Singletary, K Hunt, E Strom, M McNeese, C Stelling, G N Hortobagyi |
Journal | Cancer
(Cancer)
Vol. 92
Issue 7
Pg. 1775-82
(Oct 01 2001)
ISSN: 0008-543X [Print] United States |
PMID | 11745249
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2001 American Cancer Society. |
Chemical References |
- Antineoplastic Agents
- Doxorubicin
- Cyclophosphamide
- Paclitaxel
- Fluorouracil
|
Topics |
- Adenocarcinoma
(drug therapy, radiotherapy, surgery)
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Breast Neoplasms
(drug therapy, radiotherapy, surgery)
- Combined Modality Therapy
- Cyclophosphamide
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Female
- Fluorouracil
(administration & dosage)
- Humans
- Mastectomy
- Middle Aged
- Paclitaxel
(therapeutic use)
- Remission Induction
- Survival Analysis
|